Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...
An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...
The Manila Times on MSN4d
AstraZeneca wants to do clinical trials in PH – RoqueMULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...
AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...
AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...
Cambridge headquartered global pharma company AstraZeneca is investing C$820 million (US$570m) in Canada, creating more than ...
New approval brings the medicine to an earlier treatment setting and a broader patient population.
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback